Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours
Authors:
- J K RamageJRJ K Ramage
- A H G DaviesADA H G Davies
- J ArdillJAJ Ardill
- N BaxNBN Bax
- M CaplinMCM Caplin
- A GrossmanAGA Grossman
- R HawkinsRHR Hawkins
- A M McNicolAMA M McNicol
- N ReedNRN Reed
- R SuttonRSR Sutton
- R ThakkerRTR Thakker
- S AylwinSAS Aylwin
Open Access
Abstract
### 1.1 Genetics ### 1.2 Diagnosis If a patient presents with symptoms suspicious of a gastroenteropancreatic NET: ### 1.3 Imaging ### 1.4 TherapyKeywords
This publication has 184 references indexed in Scilit:
- A 5‐decade analysis of 13,715 carcinoid tumorsCancer, 2003
- Ki67, E-CADHERIN, AND p53 AS PROGNOSTIC INDICATORS OF LONG-TERM OUTCOME AFTER LIVER TRANSPLANTATION FOR METASTATIC NEUROENDOCRINE TUMORSTransplantation, 2002
- 131I-MIBG radionuclide therapy is safe and cost-effective in the control of symptoms of the carcinoid syndromeEuropean Journal of Surgical Oncology, 2001
- Toxicity of high-activity 111In-Octreotide therapy in patients with disseminated neuroendocrine tumoursNuclear Medicine Communications, 2000
- Surgery to Cure the Zollinger–Ellison SyndromeNew England Journal of Medicine, 1999
- Orthotopic liver transplantation in the treatment of metastatic neuroendocrine tumors of the liverLiver Transplantation and Surgery, 1995
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993
- Octreotide and interferon alfa: A new combination for the treatment of malignant carcinoid tumoursEuropean Journal of Cancer, 1992
- Carcinoid Tumor of the Appendix: Treatment and PrognosisNew England Journal of Medicine, 1987
- Effects of Leukocyte Interferon on Clinical Symptoms and Hormone Levels in Patients with Mid-Gut Carcinoid Tumors and Carcinoid SyndromeNew England Journal of Medicine, 1983